These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23973211)

  • 21. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
    Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
    Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?
    Wielens J; Headey SJ; Rhodes DI; Mulder RJ; Dolezal O; Deadman JJ; Newman J; Chalmers DK; Parker MW; Peat TS; Scanlon MJ
    J Biomol Screen; 2013 Feb; 18(2):147-59. PubMed ID: 23139382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and characterization of novel allosteric FAK inhibitors.
    Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
    Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based discovery of cellular-active allosteric inhibitors of FAK.
    Tomita N; Hayashi Y; Suzuki S; Oomori Y; Aramaki Y; Matsushita Y; Iwatani M; Iwata H; Okabe A; Awazu Y; Isono O; Skene RJ; Hosfield DJ; Miki H; Kawamoto T; Hori A; Baba A
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1779-85. PubMed ID: 23414845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
    Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
    J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of indoline-based, natural-product-like compounds as probes of focal adhesion kinase signaling pathways.
    Poondra RR; Kumar NN; Bijian K; Prakesch M; Campagna-Slater V; Reayi A; Reddy PT; Choudhry A; Barnes ML; Leek DM; Daroszewska M; Lougheed C; Xu B; Schapira M; Alaoui-Jamali MA; Arya P
    J Comb Chem; 2009 Mar; 11(2):303-9. PubMed ID: 19146410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
    van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
    Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of surface plasmon resonance screening of a diverse chemical library for the discovery of protein tyrosine phosphatase 1b binders.
    Zeder-Lutz G; Choulier L; Besse M; Cousido-Siah A; Ruiz Figueras FX; Didier B; Jung ML; Podjarny A; Altschuh D
    Anal Biochem; 2012 Feb; 421(2):417-27. PubMed ID: 22037289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
    Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
    Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
    Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
    J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis.
    Edink E; Rucktooa P; Retra K; Akdemir A; Nahar T; Zuiderveld O; van Elk R; Janssen E; van Nierop P; van Muijlwijk-Koezen J; Smit AB; Sixma TK; Leurs R; de Esch IJ
    J Am Chem Soc; 2011 Apr; 133(14):5363-71. PubMed ID: 21322593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening.
    Amano Y; Tanabe E; Yamaguchi T
    Bioorg Med Chem; 2015 May; 23(10):2310-7. PubMed ID: 25862210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of fragments for kinase inhibitor design: decoration is key.
    Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
    J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.